Volume 10, Issue 2 (6-2020)                   JABS 2020, 10(2): 2206-2225 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zahiri M, Parviz S, Hosseini S J. Use of Stem Cells in the Treatment of Myocardial Infarction. JABS 2020; 10 (2) :2206-2225
URL: http://jabs.fums.ac.ir/article-1-1598-en.html
1- Department of Anatomical Sciences, Faculty of Medical Sciences, Bushehr University of Medical Sciences, Bushehr, Iran
2- Department of Cellular and Molecular Sciences, Faculty of Science, the Persian Gulf University, Bushehr, Iran , shsahab5@gmail.com
3- Department of Biotechnology, the Persian Gulf Research and Studies Center, the Persian Gulf University, Bushehr, Iran
Abstract:   (2959 Views)
Considerable research has been done in the past few decades to treat ischemic heart disease (stroke). Although drug therapies can improve heart disease and reduce mortality in heart failure, none is able to regenerate damaged heart tissue. Therefore, stem cell-based therapies are considered as new approaches to correcting heart tissue remodeling. Since the depletion of cardiac muscle cells at the beginning of the myocardial infarction act as a stimulus for myocardial remodeling, the ability to replace these cells with their healthy counterparts is an effective treatment for many types of cardiovascular diseases.
In this study, we reviewed the advances made in the treatment of myocardial infarction through cell therapy.
 

 
Full-Text [PDF 1174 kb]   (2350 Downloads)    
Type of Study: Review | Subject: Cellular-Molecular Biology
Received: 2017/11/22 | Accepted: 2020/01/18 | Published: 2020/09/19

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advanced Biomedical Sciences

Designed & Developed by: Yektaweb

Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)